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Abstract: The purpose of this review is to discuss the impact of nanocarriers administered by 
pulmonary route to treat and to diagnose respiratory and non respiratory diseases. Indeed, during 
the past 10 years, the removal of chloroﬂ  uorocarbon propellants from industrial and household 
products intended for the pulmonary route has lead to the developments of new alternative 
products. Amongst these ones, on one hand, a lot of attention has been focused to improve the 
bioavailability of marketed drugs intended for respiratory diseases and to develop new concepts 
for pulmonary administration of drugs and, on the other hand, to use the pulmonary route to 
administer drugs for systemic diseases. This has led to some marketed products through the 
last decade. Although the introduction of nanotechnology permitted to step over numerous 
problems and to improve the bioavailability of drugs, there are, however, unresolved delivery 
problems to be still addressed. These scientiﬁ  c and industrial innovations and challenges are 
discussed along this review together with an analysis of the current situation concerning the 
industrial developments.
Keywords: nanotechnology, nanocarriers, nanoparticle, liposome, lung, pulmonary drug 
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Introduction
The removal of chloroﬂ  uorocarbon (CFC) propellants from industrial and household 
products, agreed by over 165 countries throughout the world, has lead to the 
developments of new alternative products. The timetable for this process is outlined 
in the Montreal protocol on substances that deplete the ozone layer document and in 
several subsequent amendments. These necessary changes offered the opportunity to 
the pharmaceutical companies and to research workers to develop new strategies to 
administer drugs by pulmonary route. These ones can be subdivided into two major 
parts, namely for the drugs intended on one hand for respiratory diseases and on the 
other hand for systemic diseases. In this second status, the lungs are only considered 
as a portal of entry for systemic drug delivery.
To replace CFC propellants, hydroﬂ  uoroalkanes (HFAs) are the new suggested 
alternative propellants for CFCs-12 and -114. Their potential for damage to the ozone 
layer is nonexistent, and while they are greenhouse gases, their global warming poten-
tial is a fraction (one-tenth) of that of CFCs. Replacement formulations for several 
inhalant respiratory medications have been or are being studied and tested, to assume 
the transition to these HFA or CFC-free pressurized metered dose inhalers (pMDIs) 
which will be complete by a near future. Currently, several CFC-free formulations 
are already available on the market throughout the world. Beside these new marketed 
devices, other comprising capsules containing powders called dry powder inhalers 
(DPIs) were also developed recently to avoid the use of chloroﬂ  uorocarbon propellants. International Journal of Nanomedicine 2008:3(1) 2
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To optimize the delivery of drugs, in this ﬁ  eld, particular 
considerations have been focused on the forms (geometric 
design) of the particles, their physical states (amorphous or 
crystalline state) and their sizes ranging from the nanometric 
to the micrometric scale (Courrier et al 2002). In this ﬁ  eld, 
it was also suggested to use the nanotechnology concept in 
order to increase the bioavailability of drugs administered 
by pulmonary route.
Face to these technological progresses, recently, advances 
have been also done in order to administer drugs via targeting 
dosage forms by pulmonary route for systemic applications. 
The conception of these new drug delivery systems (DDS) is 
to better control drug pharmacokinetics, pharmacodynamics, 
non-speciﬁ  c toxicity, immunogenicity and biorecognition 
of systems in the quest for improved efficacy. The 
rationale for the development of aerosol drug delivery 
systems for systemic delivery is based on the adoption 
of a multidisciplinary approach to the targeted delivery 
and release of drugs, underpinned by nanoscience and 
nanotechnology combining polymer science, pharmaceutics, 
bioconjugate chemistry and molecular biology. Therefore, 
this breakthrough is made possible by the development of 
various types of nanosystems resulting from cutting-edge 
researches based on pluridisciplinarity approaches. From the 
ﬁ  rst immunoliposomes targeting to pulmonary endothelium 
proposed in 1990 by Maruyama et al (1990) and today, there 
was an explosion in the number of nanocarriers also called 
nanodevices or nanosystems which are deﬁ  ned as particles 
having a size ranging from 1 nm to 1 µm. To be suitable for 
pulmonary drug delivery, these ones are either made of lipids 
(liposomes, niosomes, microemulsions, lipidic micelles, 
solid lipid nanoparticles) or composed of polymers (polymer 
micelles, dendrimers, polymeric nanoparticles, nonogels, 
nanocapsules). These systems are exploited for therapeutic 
purpose to carry the drug in the body in a controlled manner 
from the site of administration to the therapeutic target. This 
implies the passage of the drug molecules and drug delivery 
system across numerous physiological barriers, which 
represent the most challenging goal in drug targeting.
In general nanocarriers aim to minimize drug degrada-
tion and loss, prevent harmful side effects and increase the 
availability of the drug at the disease site. Localized therapy 
of the target organ generally requires smaller total doses 
to achieve clinically effective results. To reach this goal, 
nanocarriers can be engineered to slowly degrade, react to 
stimuli and to be site speciﬁ  c. Targeting mechanisms can be 
either passive or active. An example of passive targeting is 
the preferential accumulation of chemotherapeutic agents 
in solid tumors as a result of the differences in the vascu-
larization of the tumor tissue compared with healthy tissue. 
Active targeting involves the chemical “decorating” of the 
surface of drug carriers with molecules enabling them to be 
selectively attached to diseased cells. Nanosystems were 
also found useful to improve the performance of imaging 
techniques applied for the in vivo diagnosis of tumors. In 
this case, colloid metals are often incorporated in the nanode-
vice. Nanoscience and nanotechnology are thus the basis 
of innovative delivery techniques that offer great potential 
beneﬁ  ts to patients and new markets to pharmaceutical and 
drug delivery companies.
Aerosol administration of the therapeutics to the pulmo-
nary epithelium for systemic delivery represents a signiﬁ  cant 
opportunity for many classes of drugs and applications, 
including anti-tumor therapy, gene therapy, AIDS therapy, 
radiotherapy, in the delivery of macromolecules as peptides 
and proteins or small molecules as antibiotics, virostatics 
and vaccines. Advantages of aerosol administration include: 
(i) more rapid absorption into the systemic circulation (this 
may be speciﬁ  cally important for drugs where circulation 
(this may be especially important for drugs where fast onset 
of action is critical), and (ii) higher bioavailability than with 
other non-invasive modes of administration. This is certainly 
true for the delivery of peptides and proteins relative to oral 
administration, and is also true for many small molecules 
where ﬁ  rst-pass metabolism or efﬂ  ux transporters limit oral 
bioavailability.
Anatomy and physiology of human 
respiratory tract
The respiratory system works with the circulatory system 
to deliver oxygen from the lungs to the cells and remove 
carbon dioxide, and return it to the lungs to be exhaled. The 
exchange of oxygen and carbon dioxide between the air, 
blood and body tissues is known as respiration. Healthy lungs 
take in about 1 pint of air about 12–15 times each minute. All 
of the blood in the body is passed through the lungs every 
minute. The respiratory tract is divided into two main parts: 
the upper respiratory tract, consisting of the nose, nasal cavity 
and the pharynx; and the lower respiratory tract consisting 
of the larynx, trachea, bronchi and the lungs (Figure 1). The 
trachea, which begins at the edge of the larynx, divides into 
two bronchi and continues into the lungs. The trachea allows 
air to pass from the larynx to the bronchi and then to the lungs. 
The bronchi divide into smaller bronchioles which branch 
in the lungs forming passageways for air. The terminal parts 
of the bronchi are the alveoli. The alveoli are the functional International Journal of Nanomedicine 2008:3(1) 3
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units of the lungs and they form the site of gaseous exchange 
(Marieb 2005).
Alveoli
The blood barrier between the alveolar space and the pulmo-
nary capillaries is very thin to allow for rapid gas exchange. 
During inspiration, oxygen diffuses through the alveoli walls 
and the interstitial space, into the blood. Carbon dioxide 
diffuses in the opposite direction during exhalation. Alveoli 
are small and there are approximately 300 million of them 
in each lung. Although alveoli are tiny structures, they have 
a very large surface area in total (~100 m2) for performing 
efﬁ  cient gas exchange.
The alveoli form a honeycomb of cells around the spiral, 
cylindrical surface of the alveolar duct. The exposed alveolar 
surface is normally covered with a surface ﬁ  lm of lipoprotein 
material.
There are several types of pulmonary alveolar cells. Type I 
(or small type A), are non-phagocytic, membranous pneumo-
cytes. These surface-lining epithelial cells are approximately 
5 µm in thickness and possess thin squamous cytoplasmic 
extensions that originate from a central nucleated portion. 
These portions do not have any organelles and hence they are 
metabolically dependent on the central portion of the cell. This 
reduces their ability to repair themselves if damaged.
Attached to the basement membrane are the larger alveo-
lar cells (Type II, type B or septal cells). These rounded, 
granular, epithelial pneumocytes are approximately 10 to 
15 µm tick. There are 6 to 7 cells per alveolus and these 
cells possess great metabolic activity. They are believed to 
produce the surfactant material that lines the lung and to be 
essential for alveolar repair after damage from viruses or 
chemical agents (Washington et al 2001).
Amongst, the important roles of the lungs, one can cite: (i) 
supply oxygen, (ii) remove wastes and toxins, and (iii) defend 
against hostile intruders. The lungs have three dozen distinct 
types of cells. Some of these cells scavenge foreign matter. 
Others have cilia that sweep the mucous membranes lining 
the smallest air passages. Some cells act on blood pressure 
control, while others spot infection invaders.
alveoli
Upper Respiratory Tract
Lower Respiratory Tract
Pharynx
Nasal cavity
Larynx
Trachea
Primary bronchi
Lungs
Figure 1 Regions of the respiratory system.International Journal of Nanomedicine 2008:3(1) 4
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The respiratory system is susceptible to a number of 
diseases, and the lungs are prone to a wide range of disorders 
caused by genetic factors, infection and pollutants in the air. 
The most common problems of the respiratory system are:
• Asthma
• Bronchiolitis
•  Chronic obstructive pulmonary disease (COPD)
• Common  cold
• Cough
• Cystic  ﬁ  brosis (CF)
• Lung  cancer
• Pneumonia
• Pulmonary  hypertension
•  Respiratory diseases of newborns.
Mechanism of deposition
of particles and their becoming
into the lungs after inhalation
Aerosols are suspensions of solid or liquid particles in a 
gas (usually air). The particulate portion of an aerosol is 
referred to as particulate matter, or PM. Particulate matter 
is a generic term applied to chemically heterogeneous dis-
crete liquid droplets or solid particles. The metric used for 
describing PM is the micron, or micrometer (10-6 meter). 
The PM in an aerosol can range in size from 0.001 to greater 
than 100 microns in diameter. Particles intended to be 
administered by pulmonary route are generally categorized 
based on size:
•  Coarse particles are larger than 2 microns in diameter
•  Fine particles are between 0.1 and 2 microns in diameter
• Ultraﬁ  ne particles are less than 0.1 micron
Most aerosol particles are polydisperse. They have a wide 
range of particle sizes that must be characterized by statisti-
cal measures. In some cases, such as with an ink jet printer, 
it is desirable to have a monodisperse aerosol with particles 
of equal size.
Principal mechanisms of respiratory 
deposition
The deposition of inhaled particles in the different regions 
of the respiratory system is very complex, and depends on 
many factors. Some of the factors inﬂ  uencing respiratory 
deposition include:
• Breathing  rate
•  Mouth or nose breathing
• Lung  volume
• Respiration  volume
•  Health of the individual
•  Bifurcations in the airways result in a constantly changing 
hydrodynamic ﬂ  ow ﬁ  eld.
Depending on the particle size, airﬂ  ow, and location in the 
respiratory system, particle deposition occurs via on of the 
following principal mechanisms:
Impaction
Each time the airﬂ  ow changes due to a bifurcation in the 
airways, the suspended particles tend to travel along their 
original path due to inertia and may impact on an airway 
surface. This mechanism is highly dependent on aerodynamic 
diameter, since the stopping distance for very small particles 
is quite low. Impaction occurs mostly in the case of larger 
particles that are very close to airway walls, near the ﬁ  rst 
airway bifurcations. Therefore, deposition by impaction is 
greatest in the bronchial region. Impaction accounts for the 
majority of particle deposition on a mass basis.
Sedimentation
Sedimentation is the settling out of particles in the smaller 
airways of the bronchioles and alveoli, where the air ﬂ  ow 
is low and airway dimensions are small. The rate of sedi-
mentation is dependent on the terminal settling velocity of 
the particles, so sedimentation plays a greater role in the 
deposition of particles with larger aerodynamic diameters. 
Hygroscopic particles may grow in size as they pass through 
the warm, humid air passages, thus increasing the probability 
of deposition by sedimentation.
Interception
Interception occurs when a particle contacts an airway surface 
due to its physical size or shape. Unlike impaction, particles 
that are deposited by interception do not deviate from their 
air streamlines. Interception is most likely to occur in small 
airways or when the air streamline is close to an airway wall. 
Interception is most signiﬁ  cant for ﬁ  bers, which easily con-
tact airway surfaces do to their length. Furthermore, ﬁ  bers 
have small aerodynamic diameters relative to their size, so 
they can often reach the smallest airways.
Diffusion
Diffusion is the primary mechanism of deposition for 
particles less than 0.5 microns in diameter and is governed 
by geometric rather than aerodynamic size. Diffusion is the 
net transport of particles from a region of high concentration 
to a region of lower concentration due to Brownian motion. 
Brownian motion is the random wiggling motion of a 
particle due to the constant bombardment of air molecules. International Journal of Nanomedicine 2008:3(1) 5
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Diffusional deposition occurs mostly when the particles have 
just entered the nasopharynx, and is also most likely to occur 
in the smaller airways of the pulmonary (alveolar) region, 
where air ﬂ  ow is low.
Absorption – bioavailability of drugs
Although inhaled drugs have been used for over 50 years 
to treat airway disease and are in development or being 
considered for the treatment of many other lung diseases, 
insulin is at present time the only one representative inhaled 
drug on the market for systemic disease. Exubera® (insulin 
human [rDNA origin] inhalation powder is the ﬁ  rst diabetes 
treatment which can be inhaled. Exubera® helps control high 
blood sugar, works in adults with type 1 diabetes and with 
type 2 diabetes as well (Adjei et al 1997). This therapeutic 
success has lead a number of other companies to investigate 
and to advance clinical trials as inhaled formulations for 
systemic applications with a variety of large molecules (leu-
prolide, a luteinizing hormone-releasing hormone (LHRH) 
analogue, …) (Patton et al 1999). Recent advances in the 
development of particle technologies and devices now make 
it possible to formulate, stabilize, and accurately deliver 
almost any drug to the lungs.
The pulmonary membrane is naturally permeable to 
small molecule drugs and to many therapeutic peptides and 
proteins. The epithelium of the lung, the signiﬁ  cant barrier 
to absorption of inhaled drugs, is thick (50–60 µm) in the 
trachea, but diminishes in thickness to an extremely thin 
0.2 µm in the alveoli (Patton 1996). The change in cell types 
and morphology going from trachea, bronchi, and bronchioles 
to alveoli is very dramatic. The lungs are for more permeable 
to macromolecules than any other portal of entry into the body. 
Some of the most promising therapeutic agents are peptides 
and proteins, which could be inhaled instead of injected, 
thereby improving compliance (Patton 1996). Particularly, 
peptides that have been chemically altered to inhibit peptidase 
enzymes exhibit very high bioavailabilities by the pulmonary 
route (Schanker 1978). Indeed, natural mammalian peptides, 
les than 30 amino acids (somatostatin, vaso active intestinal 
peptide [VIP], and glucagons), are broken down in the lung 
by ubiquitous peptidases and have very poor bioavailabilities. 
Conversely, proteins with molecular weights between 6000 
and 50,000 Da are relatively resistant to most peptidases 
and have good bioavailabilities following inhalation (Patton 
et al 2004). For larger proteins, the bioavailabilities and 
absorption mechanisms are not well completely elucidated. 
For larger molecules such as proteins and peptides, airway 
epithelial junctions may be leakier than those in alveoli; 
the greater the fraction of drug deposited in the alveoli or 
deep lung, the higher the bioavailability for macromolecules 
like peptides or proteins (Patton et al 1999). Then, the 
absorption of exogenous macromolecules could be result 
from a combination of tight junctions and endocytic vesicles 
by processes that are diffusion-limited. There is evidence that 
for certain endogenous molecules that normally occur in lung 
lining ﬂ  uids, eg, albumin, immunoglobulins and transferring, 
they are speciﬁ  c receptors mediated transport mechanisms 
on the alveolar epithelial cell that enable these proteins to be 
absorbed at higher rates than expected. For all days, plasma 
proﬁ  les resulting from inhaled drugs are a composite of drug 
absorbed across markedly different epithelia, and at this time 
it is very difﬁ  cult to know what roles the different cells play 
in the absorption process. Although the pulmonary membrane 
is rich in antiproteases, aggregation of inhaled proteins will 
stimulate opsonization (coating) by special proteins in the lung 
lining ﬂ  uids, which will then mark the aggregated proteins 
for phagocytosis and intracellular enzymatic destruction 
(Patton et al 2004). These enzymes are anchored in the 
plasma membranes of all cells and attack peptides at the ends 
of the amino acid chain, releasing one or two amino acids at 
a time. Proteins are usually poor substrates for peptidases, 
partly because the ends of their amino acid chains are often 
tucked into the globular structure of the protein and are not 
available for hydrolysis. In addition, the large size of proteins 
may preclude their ﬁ  t into the catalytic clefts of the peptidase 
structures (Patton et al 2004). Thus, proteins can move about 
the body through the circulatory system and in the interstitum 
of tissues and remain “resistant” to peptidases that reside 
on the surfaces of all vessels, cells, and epithelial surfaces. 
Proteins are hydrolyzed by a different class of enzymes (ie, 
proteases), which are strictly controlled in the body and are 
located in specialized organelles (endosomes, lysosomes) 
(Patton 1996; Patton et al 2004).
Small peptides and proteins are absorbed more rapidly 
after inhalation than after subcutaneous injection. For other 
small molecules, inhalation is also a fast way to get into 
the body because drug efﬂ  ux transporters and metabolizing 
enzymes are present in the lung at much lower levels than 
the gastrointestinal tract (Brown et al 1983; Colthorpe et al 
1992; Niven et al 1994, Colthorpe et al 1995; Niven et al 
1995). Lipophilic small molecules are absorbed extremely 
fast, t1/2 absorption being approximately 1–2 minutes. Water-
soluble small molecules are absorbed rapidly, t1/2 absorption 
being approximately 65 minutes. Small molecules can exhibit 
prolonged absorption if they are highly soluble or highly 
cationic (Niven et al 1994).International Journal of Nanomedicine 2008:3(1) 6
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Although the rapid absorption of molecules has many 
conceivable medical uses, there are situations when one 
might want to slow the absorption of an inhaled small 
molecule, either to keep it acting longer locally in lung, 
or to regulate its absorption into the body. Very insoluble 
molecules that slowly dissolve from the inhaled particle may 
stick in the lung for many hours or even days. Fluticasone 
propionate, amphothericin B, and all-trans retinoic acid are 
absorbed from the lungs over a period of hours, due in part to 
their slow dissolution rate from relatively insoluble lipophilic 
particles (Brooks et al 2000; Beyer et al 1994). Encapsulation 
in slow release particles such as nanoparticles and liposomes 
can also be used to control absorption.
The bioavailability of peptides and proteins is 10–200 
times greater by pulmonary route as compared with other 
non-invasive routes (Patton 1996). This fact can be attributed 
to the considerable absorptive surface at the air interface, 
covered by an extremely small volume of ﬂ  uid (10–20 ml) 
and the entire cardiac output rushes through its capillary 
network, which lies fractions of a micron beneath the 
absorptive surface (Patton 1996). Due to this physiological 
and anatomical peculiarity, an inhaled aerosol can be widely 
dispersed and deposited in quite high concentrations in close 
proximity to the blood stream. Like the interior of the body, 
the surface ﬂ  uids of the lung contain also antiproteases that 
inhibit the enzymatic breakdown of proteins. The release of 
proteases into the lung ﬂ  uids by immune cells usually only 
occurs during infection and chronic inﬂ  ammation which 
can cause the eventual destruction of the lung (such as with 
cystic ﬁ  brosis or emphysema). The high bioavailabilities 
of “blocked” peptides can be attributed either because they 
are linked into a ring like cyclosporine (and thus have no 
exposed ends) or they have chemical modiﬁ  cations of their 
C or N terminal ends which block peptidase attack (Patton 
et al 2004). Most of these peptides were derived from natural 
peptides that were too peptidase sensitive to make them 
useful therapeutic drugs. Clearly, susceptibility to enzymes 
is one of the most powerful determinants of a peptide’s 
bioavailability through the lungs, and the use of blocking 
chemistry can make an ineffective peptide into one with high 
bioavailability and great medical value (Patton et al 2004).
One possible cause of low bioavailability of larger pro-
teins is precipitation or aggregation in the alveolar lining 
ﬂ  uid. As an aerosol particle settles in the lung, it contacts 
and is enveloped by at least a monolayer of lung surfactant 
(Patton 1996). Any aggregates of undissolved protein will be 
opsonized (coated) with various immune and non immune 
proteins that mark a particle for macrophage ingestion that, 
in the case of proteins, usually means enzymatic degradation. 
Because larger proteins are slowly absorbed by the lungs, 
they have a long time to clump and aggregate and are cleared 
by alveolar macrophages. Lombry et al demonstrated that a 
primary source of elimination of inhaled macromolecules 
after delivery to the lungs and before absorption into the sys-
temic circulation owed to clearance by alveolar macrophages 
(AM). Therefore, this fact may have important ramiﬁ  cations 
on the development of inhalation as an attractive mode of 
administration of therapeutic proteins to the blood stream.
Before discussing the interest of nanotechnology applied 
to deliver a drug efﬁ  ciently into the lungs, it is important 
to mention some practical issues with inhalation delivery. 
First of all, to reach the alveoli, the drug must be inhaled as 
particles with aerodynamic diameters somewhere between 
1 and 3 µm. The way the patient inhales, the form and the 
size of the particles constituting the aerosol will have a con-
siderable impact on the eventual primarily deposition in the 
conducting airways (trachea, bronchi, and bronchioles) or in 
the alveoli. Large aerosol particles are not absorbed intact 
since they must dissolve before to be absorbed. Material 
that does not reach the lungs is deposited in the device or 
oropharynx of the patient.
Signiﬁ  cance of nanotechnology
by pulmonary route
Pulmonary drug delivery offers local targeting for the 
treatment of respiratory diseases and increasingly appears 
to be a viable option for the delivery of drugs systemically. 
Pulmonary delivery is carried out in a variety of ways – via 
aerosols, metered dose inhaler systems, powders (dry powder 
inhalers) and solutions (nebulizers), which may contain 
nanostructures such as micelles, liposomes, nanoparticles, 
and microemulsions. Research into lung delivery is driven 
by the potential for successful protein and peptide drug 
delivery by this route and by the promise of an effective 
delivery mechanism for gene therapy (eg, in the treatment 
of cystic ﬁ  brosis) (Okumura et al 1997), as well as the 
need to replace chloroﬂ  uorocarbon propellants in metered 
dose inhaler systems. However, the success of pulmonary 
delivery of protein drugs is diminished by proteases in the 
lung, which reduce their overall bioavailability, and by the 
barrier between capillary blood and alveolar air (the air-blood 
barrier). Therefore, adjuvants such as absorption enhancers 
and protease inhibitors are sometimes required to enhance 
the pulmonary absorption of such macromolecular or poorly 
absorbable drugs. Niven and Byron reported that adjuvants 
such as oleic acid, oleyl alcohol, and Span 85 can increase International Journal of Nanomedicine 2008:3(1) 7
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the transfer rate of disodium ﬂ  uorescein in isolated rat lungs 
(Niven and Byron 1990). Yamamoto et al (1997) reported 
that the pulmonary absorption of insulin was enhanced in 
the presence of various adjuvants such as glycocholate, 
surfactin, Span 85, and nafamostat. They reported also that 
n-lauryl β-D-maltopyranoside (LM), linoleic acid-HCO60 
(hydrogenated caster oil) mixed micelles (MM), and sodium 
glycocholate (NaGC) all effectively enhanced the pulmonary 
absorption of ﬂ  uorescein isothiocyanate dextrans (FDs) 
and insulin. These adjuvants did not cause severe mucosal 
damage of rat lung, as determined by the leakage of Evans 
blue from the systemic circulation (Yamamoto et al 1997). 
These ﬁ  ndings suggested that the use of absorption enhancers 
and protease inhibitors would be a useful approach for 
improving the pulmonary absorption of biologically active 
drugs like peptides. Furthermore, besides the importance of 
the choice of excipients to increase the pulmonary absorption 
of drugs, the design (size, shape, and aerodynamic properties) 
of the dosage forms (nanocarriers) can contribute also to the 
improvement of the treatment.
Micelles
A successful drug carrier system needs to demonstrate opti-
mal drug loading and release properties, long shelf-life and 
low toxicity. Colloidal systems, such as micellar solutions, 
vesicle and liquid crystal dispersions, as well as nanopar-
ticle dispersions consisting of small particles of 10–400 nm 
diameter show great promise as carriers in pulmonay drug 
delivery systems. Drugs can be trapped in the core of a 
micelle and transported at concentrations even greater than 
their intrinsic water solubility. A hydrophilic shell can form 
around the micelle, effectively protecting the contents. In 
addition, the outer chemistry of the shell may prevent rec-
ognition by the reticuloendothelial system, and therefore 
early elimination from the bloodstream. A further feature 
that makes micelles attractive is that their size and shape can 
be changed. Chemical techniques using crosslinking mol-
ecules can improve the stability of the micelles and their 
temporal control. Micelles may also be chemically altered 
to selectively target a broad range of disease sites.
Amphiphilic macromolecules self-assemble to nano-
scopic core/shell structures in an aqueous environment, 
namely polymeric micelles that can encapsulate water insolu-
ble drugs, proteins and DNA, and target therapeutics to their 
site of action in a passive or active way. Polymeric micelles 
share many structural and functional features with natural 
transport system, eg, virus and lipoproteins. The versatility 
of the synthetic chemistry in polymeric micelles is a bonus 
providing opportunities to design appropriate nano-carriers 
for individual delivery requirements. Development of nano-
engineered polymeric micellar formulations that can address 
the problem of drug resistance correspond to one focus of 
this drug targeting dosage form. In this context, the effect 
of chemical manipulations on the encapsulation, release, 
bio-distribution and cellular interaction of the polymeric 
nanocarrier is assessed to select appropriate chemistries for 
optimized delivery of P-glycoprotein substrates to resistant 
tumors. Another focus of this nanometric dosage form is to 
improve the solubilization of a poorly water soluble drug 
intented to be administered via pulmonary route.
The advantages of polymeric micelles include better 
stability than surfactant micelles, ability to solubilize an 
adequate amount of hydrophobic drugs, prolonged circula-
tion times in vivo, and capability to accumulate in the target 
organs. In this ﬁ  eld, Jones and Leroux designed beclometha-
sone dipropionate-loaded polymeric micelles directly admin-
istrable to the lung in nanoparticle sizes in inhalation dosage 
form intended to be an effective means of treating asthma and 
chronic pulmonary obstructive disease. This concept was able 
to be achieved since the polymeric micelles are able to evade 
the mononuclear phagocytic system due to their bulky hydro-
philic outer shell and sustain the release of the drug (Marsh 
et al 2003). In addition, drug loaded polymeric micelles are 
strongly suggested to pass through the mucus layer associ-
ated with bronchial inﬂ  ammatory diseases directly to their 
receptors in the epithelial cells. For these reasons, the poly-
meric micelles are very beneﬁ  cial in delivering hydrophobic 
corticosteroids, such as beclomethasone dipropionate, for the 
treatment of chronic pulmonary obstructive disease since the 
inability of such drugs to penetrate through the mucus layer to 
reach the target site, largely the result of failure in treatment 
in the past. In addition, it was also reported that a mamma-
lian secreted phospholipase A2 (PLA2) was able to degrade 
pegylated phosphatidyl ethanolamine (Davidsen et al 2001; 
Vermehren et al 2001). This ﬁ  nding supported the potential 
of pulmonary delivery micelles to target glucocorticosteroids 
to the inﬂ  ammed tissues of the lung.
In this context, Gaber et al evaluated the potential of using 
poly-(ethylene oxide)-block-distearoyl phosphatidylethanol-
amine (mPEG-DSPE) polymer to prepare beclomethasone 
dipropionate loaded micelles with high entrapment efﬁ  ciency 
and mass median aerodynamic diameter of less than 5 µm, 
and demonstrated their sustained release properties. The 
entrapment efficiency of beclomethasone dipropionate, 
effects of drug-polymer molar ratio on particle size, physi-
cochemical properties, in vitro inhalation pattern, and in vitro International Journal of Nanomedicine 2008:3(1) 8
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drug release proﬁ  le of polymeric micelles were also investi-
gated by the same authors and allowed them to conclude of 
the therapeutic interest of this kind of nanocarriers.
Liposomes
The utilization of liposomal drug formulations for aerosol 
delivery has many potential advantages, including aqueous 
compatibility, sustained pulmonary release to maintain 
therapeutic drug levels and facilitated intra-cellular delivery 
particularly to alveolar macrophages (Schreier et al 1993). 
Furthermore, drug-liposomes may prevent local irritation 
and reduce toxicity both locally and systematically (Schreier 
et al 1993; Gonzalez-Rothi and Schreier 1995). Increased 
potency with reduced toxicity is characteristic of many 
drug-liposomal formulations (Cullis et al 1989). Liposomal 
aerosols (including CsA) have proven to be non-toxic in 
acute human and animal studies (Thomas et al 1991; Myers 
et al 1993; Waldrep, Arppe, et al 1997; Waldrep, Gilbert, 
et al 1997). These results suggest that drug-liposome 
aerosols should be more effective for delivery, deposition 
and retention of water-insoluble, hydrophobic, lipophilic 
compounds in contrast to water soluble compounds (Niven 
and Schreier 1990; Taylor et al 1990; Taylor and Farr 
1993). The goal of targeted drug-liposomal aerosol therapy 
is to maximize delivery and retention while minimizing 
clearance. Studies of liposomal CsA have demonstrated 
a propensity for bilayer membrane exchange both in vitro 
and in vivo (Choice et al 1995; Fahr et al 1995; Ouyang 
et al 1995).
The development of liposomal formulations for aerosol 
delivery with jet nebulizers has expanded the possibilities 
for effective utilization of aerosol based therapies in the 
treatment of pulmonary diseases. The property of sustained 
release or depot effect of liposomes has been studied 
using different tracer molecules to monitor absorption 
and clearance of liposomes from the lung. A cyclosporin 
A (CsA)-dilauroylphosphatidylcholine (DLPC) liposomal 
formulation for aerosol delivery to the lung has been 
studied by Waldrep, Nieminen, et al (1997). These authors 
determined by HPLC the pharmacokinetics of both CsA and 
liposomal carrier (labeled with 99mtechnetium (99mTc)) to 
study potential dissociation after delivery to normal mouse 
lungs. Same authors compared also the effects of pulmonary 
inﬂ  ammation on the clearance of CsA-DLPC liposomes 
with 99mTc labeled human serum albumin (HSA). Results 
indicated that 99mTc-DLPC liposome carrier is retained up 
to 16.9 times longer than the CsA half-life in normal lung 
and 7.5 times longer in inﬂ  amed lungs. Similar values were 
obtained also for 99mTc-labeled albumin (14.8 times for 
normal CsA half life (6.8 times in inﬂ  amed lungs)) (Arppe 
et al 1998)
The development of liposomal formulations, compatible 
with aerosol delivery with jet nebulizers, has also expanded 
the possibilities for more effective utilization of aerosol based 
therapies for the treatment of a variety of pulmonary diseases 
(Farr et al 1985; Gilbert et al 1988; Niven and Schreier 1990; 
Schreier et al 1993; Taylor and Farr 1993). Such utilization 
of liposomes, as aerosol delivery vehicles, has many reported 
potential advantages for clinical development, including: 
aqueous compatibility facilitated intra-cellular delivery 
particularly to alveolar macrophages and lymphocytes and 
sustained pulmonary release to maintain therapeutic drug 
levels within the lung (Schreier et al 1993; Taylor and Farr 
1993; Hung et al 1995). These factors, however, have not 
been extensively studied in the human lung.
Human studies of liposome aerosols have demonstrated 
similar retention within the normal lung, but, depending 
on the presence of inﬂ  ammation (Vidgren et al 1994; Saari 
et al 1998). Factors affecting the clearance and/or elimina-
tion of exogenous materials from normal and diseased lung 
tissues are not yet completely understood. The mucociliary 
clearance system is impaired in the diseased lung (Schreier 
et al 1993), including asthma (O’Riordan et al 1992). In 
contrast, experimental studies lead in rats with infection 
and/or associated pulmonary inﬂ  ammation have showed 
enhanced clearance of instilled drug-liposomes and inhaled 
99mTc-HSA (Connelly and Peterson 1993; Omri et al 1994). 
Thus, multiple factors could also inﬂ  uence drug-liposome 
retention times within the lung.
Using gamma scintigraphy, nebulizer systems were 
evaluated and selected for optimal aerosol targeting of 
drug-liposomes to the peripheral lung regions (Vidgren et al 
1994). However, recent studies of CsA-liposomes in other 
experimental systems have reported that CsA displays a 
unique property of rapid bilayer membrane exchange (Choice 
et al 1995; Fahr et al 1995; Ouyang et al 1995). The aerosol 
particle sizes of these labeled liposomes was 1.54 (1.64) mm 
MMAD and 2.62 (2.65) GSD by CsA and 99mTc distribu-
tion, respectively. The mean particle size of the liposomes 
in solution by Nicomp analysis was 564 nm. The clearance 
studies of 99mTc-labelled CsA-DLPC liposomes delivered to 
the lungs of normal Balb/c mice demonstrated that there was 
an apparent dissociation between CsA and 99mTc-labelled 
DLPC molecule independent of inﬂ  ammation similarly as 
it was previously described for intravenous liposomal CsA 
by Choice et al (1995), Fahr et al (1995), and Ouyang et al International Journal of Nanomedicine 2008:3(1) 9
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(1995). Therefore Arppe et al (1998) concluded that CsA 
clearance from the lung was unaffected by inﬂ  ammation.
Studies of pharmacokinetics lead by Arppe et al (1998) 
demonstrated that the 99mTc-DLPC (1,2 dilauroyl-sn-glycero-
3-phospholine) is retained up to 16.9 times longer than the 
pulmonary half lives of CsA (T1/2) in normal lung (7.5 times 
in inﬂ  amed lung). The pulmonary half lives of CsA (T1/2) in 
this system was unaffected by pulmonary inﬂ  ammation with 
concurrent lymphocytic inﬁ  ltration and cyclophilin binding 
proteins. While the CsA-DLPC liposomes used in this study 
were extremely stable in vitro, the results suggested that there 
was dissociation mediated by multiple uncharacterized fac-
tors in the lung following pulmonary delivery of CsA-DLPC. 
This in vivo dissociation phenomenon did not, however, 
preclude the delivery of immunosuppressive activities to the 
lung and thus, CsA-liposome aerosol therapy may be utilized 
in the treatment of chronic bronchiolar asthma and a variety 
of pulmonary diseases, such as pulmonary sarcoidosis and 
allergic hypersensitivity.
Nebulization of rehydrated freeze-dried beclometha-
sone dipropionate liposomal preparations showed that the 
output of liposomes from the nebulizer was dependent on 
the lipid used (Darwis and Kellaway 2001). Liposomes 
formed from lipids with a high Tm exhibited a low output 
of aerosols, due to aggregation during nebulization (Darwis 
and Kellaway 2001). To compare beclomethasone dipropio-
nate liposomal formulations, the same drug encapsulated in 
poly(L-lactic acid) yielded microspheres in aerosolizable 
particle size range of less than 5 µm. Nevertheless, degra-
dation of these microspheres could only release 15% of the
drug over a period of eight days (El-Baseir et al 1997). As 
a result of nanoprecipitation, anhydrous beclomethasone 
dipropionate in beclomethasone dipropionate-poly(L-lactic 
acid) nanoparticles was changed to beclomethasone dipro-
pionate monohydrate (Hyvönen et al 2005). Also, recently, 
non-phospholipid vesicles loaded with beclomethasone 
dipropionate were fabricated with non-ionic surfactant, 
polysorbate 20 (Terzano 2005). Even though the ﬁ  ne particle 
fraction (FPF) with aerodynamic diameter of less than 5 µm 
was 95% and the permeation rate through model mucosal 
barrier was greatly enhanced, the maximum entrapment 
efﬁ  ciency was only 20%.
Shahiwala and Misra compared bioavailabilities of differ-
ent pulmonary formulations intended to provide prolonged 
effective concentration of levonogestrel in plasma and to 
reduce reported side effects of orally administrated drug. 
Levonogestrel encapsulated liposomes containing 10 µg of 
drug were instilled intratracheally in rats and were compared 
with the plain drug suspension and the physical mixture also 
administrated by the same route (plain drug with liposomal 
constituents). The plasma drug concentration data of differ-
ent treatements were plotted and pharmacokinetics data were 
calculated and compared with that of oral administration. 
Percentage relative bioavailability of 97.6%, 98.6%, and 
109.9% were observed after pulmonary administration of 
plain drug formulation, physical mixture (plain drug along 
with constituents of liposomes), and liposomal formulations 
of the drug, respectively. Following oral administration, Cmax 
of 14.4 ± 0.6 ng/mL was observed at 2.1 ± 0.2 hours followed 
by subtherapeutic concentration beyond 30 ± 0.2 hours, while 
after pulmonary administration of formulations, Cmax of 4.4 
± 0.4 ng/mL, 4.2 ± 0.5 ng/mL, and 4.4 ± 0.6 ng/mL were 
observed at 6.0 ± 0.2 hours, 7.0 ± 0.2 hours, and 6.8 ± 0.2 
hours, respectively, followed by maintenance of effective 
plasma drug concentration up to 60 ± 2 hours. The studies 
lead by Shahiwala and Misra (2004) allowed to demonstrate 
on one hand superiority of pulmonary drug delivery with 
regards to maintenance of effective therapeutic concentra-
tion of the levonorgestrel in the plasma over a period of 6 to 
60 hours and on the other hand to reduce frequency of dosing 
and systemic side effects associated with oral administration 
of levonorgestrel.
Stern et al (2000) advanced the potential of liposomes 
as gene carriers. These authors demonstrated that the pre-
treatment with cationic lipid-mediated transfer of the Na+ 
K+ -ATPase pump in a mouse model in vivo augmented 
resolution of high permeability pulmonary oedema. This 
demonstration of a significant reduction in pulmonary 
edema following in vivo gene transfer allowed raising the 
possibility of gene therapy as a novel localized approach for 
pulmonary edema in clinical settings such as acute respira-
tory distress syndrome (ARDS) and lung transplantation 
(Stern et al 2000).
Microemulsions
Likewise the micellar solutions, the emulsions and micro-
emulsions are dosage forms showing numerous advantages 
providing that the surfactants used are not toxic. Anyway, 
more and more exogenous surfactants, used for treatments 
and as a precaution for acute respiratory distress syndrome 
(ARDS), are used as solutions or suspensions drug target-
ing systems. Therefore, these ones allow envisaging at once 
a respiratory treatment and a drug delivery system. These 
surfactants are considered as effective drug targeting systems 
if they don’t interfere with the therapeutic activity of the 
drug. Indeed, incorporation of a drug into micellar solutions International Journal of Nanomedicine 2008:3(1) 10
Smola et al
constituted with Cremophor® EL increases its bioavailability 
until 77% (Taljanski et al 1997).
Very few emulsions or microemulsions have been studied 
to administer drugs by the pulmonary route (Lawrence and 
Rees 2000). However, these dosage forms show numerous 
advantages compared to other drug targeting systems: easi-
ness to be manufactured and maximum of drug to be incor-
porated. Indeed, the drug being soluble into one phase, this 
one will be located preferentially into this phase, leading to 
an encapsulation close to 100%. Due to their physicochemical 
characteristics, reverse emulsions and microemulsions should 
allow to solubilize a large amount and a lot of hydrophilic 
drugs.
Several aerosol formulations designed with an external 
phase constituted of a propellant have been described. As 
example, one can cite water-in-chloroﬂ  uorocarbon reverse 
micelles including proteins and peptides stabilized by 
lecithin (Evans and Farr, 1993). Even if this dosage form is 
stable and is able to deliver peptides and proteins efﬁ  ciently 
by pulmonary route, its use should be limited since the 
Montreal protocol (1987) recommended stopping the 
production and the use of chloroﬂ  uorocarbons. Propellants 
like hydrofluoroalkanes (HFAs) or propane have been 
suggested. Reverse microemulsions stabilized by lecithin 
and using propane and dimethylether as propellants have 
been also described (Sommerville et al 2000). These 
microemulsions, characterized by mean geometric diameters 
ranged between 1 and 5 µm and by a respirable fraction up 
to 36%, showed high stability during more than 4 weeks at 
room temperature. Water-in-HFA emulsions stabilized by 
non ionic ﬂ  uorinated surfactants have been also studied in 
order to administer drugs by pulmonary route (Patel et al 
1998). Butz et al (2002) and Courrier et al (2004) studied 
new reverse miniemulsions and microemulsions based on 
ﬂ  uorinated surfactants intended for pulmonary delivery 
of drugs. Miscibility behavior studies of dipalmitoylpho
sphatidylcholine with a single-chain perﬂ  uoroalkylated 
amphiphile in Langmuir monolayers indicated that the 
(perﬂ  uorooctyl)undecyldimorpholinophosphate surfactants 
softened the lipid, which may be crucial for the performance 
of this material during the dimensional changes of the 
monolayer imposed during inhalation-exhalation cycles 
(Courrier, Vandamme et al 2003; Hiranita et al 2003). 
The evaluation of cytotoxicity of new semi-ﬂ  uorinated 
amphiphiles derived from dimorpholinophosphate allowed 
to conclude that semiﬂ  uorinated compounds with the highest 
ﬂ  uorinated chain length/total chain length ratio were the least 
toxic (Courrier, Krafft et al 2003; Courrier 2004). Moreover, 
reverse water-in-ﬂ  uorocarbon emulsions stabilized with 
these amphiphiles were found to be non-cytotoxic, or 
less cytotoxic than solutions of the same amphiphiles in 
ﬂ  uorocarbons. Administered by intranasal route to mice, 
those emulsions didn’t alter the lungs and didn’t induce 
lung inﬂ  ammatory reactions, but they induced a body weight 
decrease which was found to be reversible. These reverse 
water-in-ﬂ  uorocarbon emulsions showed their potential 
as lung delivery system by the recorded hypoglycemic 
effect after the intranasal administration of those emulsions 
incorporating insulin (Courrier et al 2004).
Micro- and nanoparticles
The terminology “microparticle” (size comprised between 
1 and 999 µm) includes the microspheres (uniform sphere 
constituted of a polymeric matrix) and the microcapsules 
(container constituted of an oily core surrounded by a thin 
polymeric membrane).
Biodegradable microspheres, designed from natural or 
synthetic polymers, have been largely used as drug targeting 
systems via different routes. Hydrophilic and lipophilic mol-
ecules can be encapsulated or incorporated into microspheres. 
Compared to liposomes, microspheres have an in vivo and 
in vitro more stable physicochemical behaviour and should 
allow a slower release and a longer pharmacological activ-
ity of the encapsulated drugs. Biodegradable microspheres 
are prepared by using varied polymers: albumin, chiotosan, 
polysaccharide (Illum, 1997), poly(lactic-co-glycolic) acid, 
poly(lactic) acid, poly(butylcyanoacrylate) and poly(lactic-
co-lysine graft lysine).
Pulmonary administration of aerosolized microspheres 
allows a sustained and prolonged release of drugs for respi-
ratory or non respiratory diseases, in this last case, the drug 
being protected against the enzymatic hydrolysis. Micro-
spheres can be produced following different requirements 
such as the morphology, the size and the porosity by varying 
different technological parameters during their preparation. 
Microspheres are less hygroscopic and are then less liable 
to swell in the presence of moisture located into the lungs 
(El Baseir and Kellaway 1998).
Studies relative to pulmonary targeted dosage forms 
using encapsulated drugs into microspheres have been 
developed recently. Different drugs have been encapsulated 
into microspheres including corticosteroids (El Baseir and 
Kellaway 1998), viruses (Greenway et al 1995; Eyles et al 
2000), proteins (Morimoto et al 2000), tuberculostatics 
(Suarez et al 2001; Zhang et al 2001), and anticancer agents 
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Chitosan-microspheres have been formulated in order to 
be spread out into hydroﬂ  uoroalkanes (HFAs), novel propel-
lant used for pressurized inhalers having a respirable fraction 
ranging up to 18% (Williams et al 2000).
Nanoparticles present the same characteristics than the 
microspheres: they are also constituted of polymers or lipids 
and drugs bound either at the surface of the particles either 
encapsulated into the vector. In this last case, a protection 
against the enzymatic degradation and a modiﬁ  ed bioavail-
ability of the drug can be envisaged and increased by a 
controlled release. These targeting systems (Kawashima 
et al 1998, 1999; Takeuchi et al 2001) can be designed for 
in vivo applications including molecules with therapeutic 
activities and radiocontrast agents or in vitro as a support for 
molecules intended for diagnosis. Manufacturing and encap-
sulating methods for drugs and the feasibility of modifying 
the surfaces of these vectors have been reviewed by different 
authors (Couvreur et al 2006; Lemarchand et al 2006). Drug 
targeting studies using these vectors by pulmonary route 
have been essentially conducted by encapsulating insulin 
(Kawashima et al 1999; Zhang et al 2001).
Large porous PLGA-particles (ρ ∼0.4 g.cm-3, d   5 µm) 
showed to be more efﬁ  cient for the pulmonary drug delivery 
of inhaled particles than small porous or not porous particles 
(ρ ∼1 ± 0.5 g.cm-3, d   5 µm) (Edwards et al 1997). This 
efﬁ  cacy was attributed to the fact that large particles aggre-
gate less and deaggregate more easily under shear forces 
than smaller, non-porous particles – all other considerations 
equal (French et al 1996; Li et al 1996) – hence they appear 
to more efﬁ  ciently aerosolize from a given inhaler device 
than conventional therapeutic particles.
Very few particles composed of biocompatible and bio-
degradable polymers have been studied for the targeting of 
drugs by pulmonary route (Zeng et al 1995; Li et al 2001). 
Synthetic polymers are much more frequently used than 
natural polymers. Even if the synthetic polymers are well 
tolerated as implants, they are not biologically inert when 
they are not biologically inert when they are used as particles 
(Armstrong et al 1996). In fact, particles having sizes rang-
ing from nanometers to micrometers can be internalized by 
macrophages and then degraded inside the cells, leading to 
a possible toxicity. Then, these solid polymeric particles can 
induce a cytotoxic (Müller et al 1996) or inﬂ  ammatory effect 
(Armstrong et al 1996).
The size of particles plays a crucial role for the appear-
ance of inﬂ  ammatory symptoms. Indeed, ultraﬁ  ne poly-
styrene particles (∼60 nm) showed much more developed 
pro-inﬂ  ammatory activities than nanoparticles having a size 
ranged between 200 and 500 nm and this, due to the much 
more pronounced importance of their speciﬁ  c area (Brown 
et al 2001).
Since 1991, solid lipid nanoparticles (SLN) have been 
developed in order to design alternative colloidal drug tar-
geting particles to liposomes and polymeric nanoparticles 
(Müller et al 2000). Indeed, SLN combine the advantages 
of the biocompatibility of lipids and the possibility of 
industrial scale up of nanoparticles. Like for polymeric 
micro- and nanoparticles, three possible loadings of drugs 
can be envisaged: (i) dispersion of drugs into the particle; 
(ii) core-membrane model containing a membrane improved 
with the drug; (iii) core-membrane model containing a core 
improved with the drug. Already, drugs like prednisolone, 
diazepam and camptotecin have been incorporated into 
SLN for pulmonary applications (Müller et al 2000). The 
key parameters determining the encapsulation rate of drugs 
into lipids are: (i) the solubility of the drug into melt lipids, 
(ii) the miscibility of the melt drugs into melt lipids, (iii) 
chemical and physical structures of the lipid solid matrix, 
and (iv) the polymorphous state of the lipids. In vitro 
release studies have showed that an encapsulated drug into 
solid lipid nanoparticles can diffuse during a period of time 
ranging from 5 to 7 weeks. Also, dispersions of solid lipid 
nanoparticles can be spray dried without signiﬁ  cant change 
of the sizes of the particles.
Others nanoparticles, based on lecithin, have been 
also studied in order to ensure their dispersion into hydro-
ﬂ  uoroalkanes (HFAs) to generate aerosolization properties 
(Dickinson et al 2001). In this study, the respirable fraction 
ranged up to 88 ± 8%. These nanoparticles showed an ideal 
deposition proﬁ  le of inhaled particles intended for systemic 
delivery of drugs.
Following the interesting results obtained at the 
outcome of the studies lead on porous and lipid particles, 
Pulmospheres™ have been made up (Dellamary et al 2000). 
These particles are made of phospholipids (ρ  0.2 g.cm–3, 
2.3 d 4.5 µm) easily to be dispersed into HFAs, from 
their sizes ranging between 50 and 300 nm and having the 
advantage to release uniform amounts of drugs when they 
are aerosolized. A prolonged release of immunoglobulins 
incorporated into these microparticles has been studied (Bot 
et al 2000).
Cyclodextrins
Cyclodextrins (CDs) are the result of the association of oli-
gosaccharides and are formed of six, seven or eight units of 
glucopyranose (α-, β- or γ-CD, respectively). The outside International Journal of Nanomedicine 2008:3(1) 12
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part of CDs has hydroxyl groups which arehydrophobic 
whereas the inner part is relatively lipophilic. Following 
the complete or partial inclusion of the drug into the cavity, 
the drug can interact by non covalent bondings with CDs, 
becoming higher soluble in an aqueous medium (Duchêne, 
Ponchel et al 1999; Duchêne, Wouessidjewe et al 1999).
β-CD seems to be the more used cyclodextrin for 
pharmaceutical development, due to the size of its cavity, the 
complexation efﬁ  ciency with drugs and their relatively low 
production costs. CDs have been studied to encapsulate drugs 
and to be used in this application to target drugs into the lungs. 
CDs are able to complex testosterone, salbutamol or rolipram 
(Rajewski and Stella 1996). Cyclodextrins can be used also 
in combination with other vectors. They are able to increase 
the encapsulation rate of drugs into microparticles and to 
modulate their releases (Duchêne et al 1999). Principally, 
they were described and used by pulmonary route for their 
pulmonary absorption promoter of peptides and proteins 
(Sayani and Chien 1996) like insulin (Chetty and Chien 
1998) or calcitonin (Kobayashi et al 1996).
CDs exert a relatively mild and reversible effect on 
the ciliary beat frequency of both chiken embyo trachea 
and human nasal adenoid tissue in vitro in a concentra-
tion-dependent manner (Sayani and Chien 1996; Irie and 
Uekama 1997).
Optimization of the pulmonary 
vector
A stable formulation of the drug targeting system depends 
of several factors: (i) the composition and the structure of 
the vector, (ii) the manufacturing process, (iii) the nature 
and the proportion of the incorporated drug. The size of the 
vector is a key parameter, in particular for the pulmonary 
administration. The optimum formulation of the vector cor-
responds to (i) a maximum efﬁ  ciency of the incorporation 
of the drug, (ii) an efﬁ  ciency of the administration which 
allows the best distribution of the drug and to generate the 
best therapeutic activity.
Protection of the pharmacological
activity of the drug
The encapsulated drugs into the vectors are protected against 
the degradation or the transformation attributable to the 
external pulmonary medium. As example, the anticancer 
drug 9-nitrocamptothecin (9NC) has been encapsulated into 
DLPC-liposomes in which the lactone for of the camptoth-
ecin has been preserved in the liposomes during pulmonary 
deposition, even in the presence of albumin (Knight et al 
2000). In fact, albumin combines with the camptothecin 
carboxyl form, involving an almost total loss of 9-NC anti-
cancer activity. The degradation of salmon calcitonin by the 
enzymes associated to the pulmonary membranes seems also 
to be avoided by encapsulating the drug into microspheres 
made of gelatine (Morimoto et al 2000).
Similarly, PLGA-microspheres can protect plasmids 
from nuclease degradation and therefore offer an effective 
approach for in vivo gene delivery especially to phagocyte 
cells, for inducing immunization. The dissolution of the drug 
into the pulmonary mucus is avoided if the drug is encapsu-
lated into the vector. For example, this is the case of encap-
sulated corticosteroids into PLA or PGLA microspheres.
Decrease of the systemic toxicity of drug
The encapsulation of drug into vectors avoids the local irri-
tations and decreases the local and systemic toxicity of the 
drug. Moreover, the targeted pulmonary administration of 
the vector allows decreasing the amount of the encapsulated 
drug, since the total amount of drug is released locally. The 
amount of effective 9NC contained in the liposomes is 10–50 
times lower than that used by other routes of administration 
(Knight et al 2000). The greater therapeutic effectiveness 
is a result of rapid absorption in the respiratory tract and, 
more speciﬁ  cally, in the pulmonary tissues, and penetration 
into the organ and tumor sites. Other studies (Koshkina et al 
2000) were investigated with 9NC-liposomes, by atomizing 
them into mice with pulmonary metastases caused by B16 
melanoma or human osteosarcoma. In both cases, the admin-
istration of 9NC-liposomes in aerosol form led to a reduction 
in pulmonary weight and number and size of metastases. 
Treatment with 9NC-liposomes appeared to be effective 
against pulmonary tumors.
Effeciency of encapsulation
Physicochemical characteristics of the drug
By choosing the drug targeting system, the physicochemi-
cal characteristics of the drug is crucial in order to allow 
a satisfactory encapsulation rate. Ionic drugs are usually 
used to be dissolved into the aqueous phase. The drug to be 
encapsulated into the liposomes has to be hydrophilic and 
water-soluble in order that the membrane of the liposome 
can be used for keeping the therapeutic molecule inside of 
the cavity and allows a prolonged release (Gonzales-Rothi 
et al 1996).
Liposomes of EYPC-cholesterol (CHOL) incorporating 
dexamethasone palmitate (DEXP), in a molar proportion of 
4:3:0.3 were studied (Benameur et al 1995). Encapsulation of International Journal of Nanomedicine 2008:3(1) 13
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the DEXP was effective (70%) in comparison with its non-
esteriﬁ  ed form ( 2%). The biological activity of DEXP was 
evaluated on blood mononuclear cells over a 24-hour period, 
measuring its anti-lymphocyte proliferation properties and its 
inhibition of interferon-γ production (Table 1). The DEXP 
incorporated into the liposomes kept its biological activity. 
Nebulization studies in animals should conﬁ  rm whether this 
vector was promising in drug delivery to the lungs.
On the contrary, a lipophilic drug is preferably used to 
be encapsulated into polymeric microspheres because of 
its homogenous dispersion into the polymeric matrix. As 
example, beclomethasone dipropionate (BDP) showed an 
encapsulation rate of 88% into PLA microspheres whereas 
sodium nedocromil was encapsulated only with a rate of 9% 
(El-Baseir et al 1998).
Physicochemical characteristics of the vector
Reasonable encapsulation rates, between 10% and 35% can 
be obtained during the formulation of liposomes (Gonzalez-
Rothi et al 1996; Suntres and Shek 1998). The physicochemi-
cal characteristics of the drug targeting system have to be 
adequately selected so that to have a maximum efﬁ  ciency 
of the encapsulation of the drug. Partially negative charged 
liposomes allow an efﬁ  cient encapsulation (70%) of cationic 
peptides (Lange et al 2001). Also, Ten et al (2002) reported 
that DMPC-liposomes allowed to encapsulate 98.8% of 
Interleukin 2 (IL-2).
Concerning the polymeric microspheres, the encapsula-
tion rates are generally higher (20%–50%) principally due to 
the existence of different technologies allowing the encap-
sulation of a drug. However, the molecular weight of the 
polymers can play on the efﬁ  ciency of the encapsulation of 
the drug. Indeed, when the PLGA has a molecular weight of 
12,500 g.mol-1, the encapsulation efﬁ  ciency for DNA reaches 
30.0% whereas a molecular weight of 50,000 g.mol-1 allowed 
an encapsulation rate of 53.3% (Wang et al 1999).
Drug delivery systems without encapsulation
Kanaoka et al (1999) showed that the presence of empty 
liposomes can also stabilize nebulized INF-γ. INF-γ 
nebulized alone is unstable, with these two cysteines 
producing intra- and intermolecular bonds then involving 
polymerization and aggregation. This method has the 
advantage of avoiding the incorporation of INF-γ in 
the liposomes as well as separating free INF-γ and 
liposomes. The liposome size remained identical before 
and after atomizing. Because they are unilamellar (UL) 
vesicles, these liposomes were too small and too rigid 
to be deformed. The size of the nebulized droplets was 
identical with or without liposomes. Therefore, liposomes 
do not interfere in the delivery of INF-γ. It was calculated 
that approximately 100 liposomes were combined with a 
molecule of INF-γ.
DPPC–CHOL (7:2) liposomes encapsulating insulin of 
various oligomerization degrees were instilled by the i.t. route 
in rats (Liu et al 1993). These studies revealed that only the 
initial response (10 min) of encapsulated hexameric insulin 
is slower than that of dimeric insulin, suggesting a slower 
permeability through the pulmonary epithelium. However, 
the hypoglycemic effect was identical for both encapsulated 
oligomers, as it was for the physical mixture of insulin and 
blank liposomes. Prolonged absorption of insulin is not due 
to encapsulation but to the liposome surface connection and 
probably to an interaction between the exogenous DPPC and 
pulmonary surfactant.
Complexes between drugs and vectors are more and more 
designed, especially in gene therapy. Cationic liposomes are 
in particular used to complex DNA. Certain drugs have been 
spray dried successfully and showed the expected therapeutic 
activity, namely the proteinic activity.
Increase of the pulmonary retention
and bio-activity
At same concentration, an encapsulated drug into a vector 
is held during a longer time inside the lungs than the 
same drug in solution. Then, the kinetic proﬁ  le of the 
therapeutic activity of the drug is prolonged when this one 
is encapsulated into the vector. In this case, the controlled 
release of the drug allows the decrease of the side effects 
due to the removal of the ﬁ  rst-pass metabolism of the drug, 
less administrations of dosage forms and a best compliance 
of the patient.
It has been showed that a half-hour after the instillation, 
the pulmonary concentration of glucocorticoids was twice 
higher when the drug is encapsulated into liposomes 
compared to the solubilized drug (Suntres and Shek 1998). 
The therapeutic activity was signiﬁ  cantly prolonged during 
more than 72 hours whereas the free glucocorticoids didn’t 
Table 1 Inhibition (%) of concavalin A stimulating proliferation 
of lymphocytes and production of interferon γ (INF-γ)a
Inhibition %  Free DEXP  Liposome-DEXP
concavalin A-stimulating   
Lymphocytes proliferation  94  94
INF-γ production  96  96
ainduced by 10-6 M of free dexamethasone palmitate (DEXP) or by DEXP loaded 
liposomes composed of EPC-Cholesterol. (Benameur et al 1995).International Journal of Nanomedicine 2008:3(1) 14
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show any therapeutic activity after 24 hours. Similar results 
have been observed by using encapsulated antibiotics into 
liposomes (Demayer et al 1993).
The pulmonary retention of the vector has also to be 
studied: it allows to determine the kinetic release of the 
drug from the vector. Generally, the drug is eliminated more 
rapidly than the vector. As example, liposome vectors and 
cyclosporine A (CsA) dissociation were studied in mice 
following pulmonary delivery (Arppe et al 1998).
A stable radioactive complex of 99mTc-liposomes DLPC/
CsA was delivered by intratracheal (i.t.) instillation. The 
99mTc –liposomes DLPC vector was retained 17 times longer 
than the half-life of CsA in a normal lung and 7.5 times longer 
than in an inﬂ  amed lung.
Determination of the kinetic drug release
Generally, the vectors are used to determine the kinetic 
release of the drug inside of the lungs. The encapsulated 
drug into the vector shows a therapeutic activity which is 
copared to the same drug in solution, at the same concentra-
tion. The kinetic release of the drug depends essentially of 
the composition and of the structure of the vector.
By using liposomes, the kinetic proﬁ  le of the drug is 
depending of the glass temperature (Tg °C) of the lipids 
used to formulate the liposomes. A high glass temperature 
means that the liposomes will be rigid and the speed of 
the drug release will be slow. For this reason, liposomes 
composed of DPPC (Tg ∼ 42 °C) will release a drug more 
slowly than liposomes composed of DLPC (Tg ∼ −2 °C) or 
of EPC (−10 ± 5 °C). Incorporation of cholesterol (CHOL) 
into the mixture of lipids will make rigid the structure (= 
membrane) of liposomes. A formulation of liposomes 
composed principally of DPPC and negative charged 
lipids like dimyristoylphosphatidylglycerol (DMPG) 
(Tg ∼ 23 °C) allowed a prolonged and sustained release 
of the encapsulated antibiotics during more than 48 hours. 
The physical interaction of a lipophilic drug and the lipids 
constituting the bilayer of liposomes will lead to a decrease 
of the Tg of the lipids used (Darwis and Kellaway 2001). 
Microparticles containing the same drug but constituted of 
different polymers showed different kinetic releases of the 
encapsulated drug. As example, PLGA microspheres (MW 
∼15,000) released 20% of a drug after 8 hours whereas 
PLA-microspheres (MW 2,000) containing the same drug 
released this one completely after the same time. The 
kinetic release of the drug is also depending of charges 
present at the surface of the particles and principally the 
electrostatic difference between the drug and the molecules 
constituting the vector, leading then to an attraction or 
repulsion. Indeed, after 2 hours, 85% of salmon calcitonin 
are released from positive charged microspheres whereas 
40% were released from negative charged microspheres 
(Morimoto et al 2000).
Therapeutic requirements
The design of a formulation can be the reflection of a 
therapeutic requirement. Indeed, for a formulation to 
be spray dried, the atomizing time has to be reduced to 
reach its maximum in order to favor the compliance of 
the patient by keeping the therapeutic activity. In this last 
case, a formulation incorporating a maximum of drug is 
then wished. To respond to these requirements, liposomes 
of DLPC containing concentrated amounts of CsA and 
budesonide (Bud) have been formulated and nebulized 
(Waldrep, Nieminen et al 1997). Formulations 40 times more 
concentrated than commercial ones and used by nebulization 
of Bud suspensions could both reduce nebulization time and 
improve patient compliance.
Cellular adhesion
Target or avoid alveolar macrophages?
Targeting drugs to alveolar macrophages has the distinct 
advantage of delivering high concentrations of drug to a 
cell that plays a central role in the progression of disease 
(tuberculosis) and in immune responses.
The microspheres can target alveolar macrophages 
(AMs) without eliciting a pulmonary inflammatory 
response in vitro (Ng et al 1998). In fact, a cell culture of 
AM, in the presence of microspheres composed of PLA, 
produces negligible quantities of oxidants and tumor 
necrosis factor alpha (TNF-α) inﬂ  ammatory cytokines. 
Interactions between PLA microspheres, marked by 
rhodamine 6 G, which is a ﬂ  uorescent agent, and AM, 
are concentration-dependent (~30% interactions with a 
concentration of 50,000 particles /mL). Endocytosis of 
the microspheres was revealed in the presence of certain 
endocytosis inhibitors – lysosomotropic agents, NH4Cl, 
and chloroquine – reducing AM – particle interaction by 
around 50%. This study demonstrated that microspheres 
can enter alveolar macrophages without activating them, 
thus enabling possible drug delivery to target macrophages, 
for example, in the case of tuberculosis.
Liposomes, due to their similar compositions of the 
pulmonary surfactant can interact with life cells like macro-
phages by different ways, namely: adsoption, endocytocis, 
exchange of lipids or fusion.International Journal of Nanomedicine 2008:3(1) 15
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Mucoadhesive systems
Bioadhesive drug delivery systems were introduced in order 
to prolong and intensify the contact between controlled 
delivery forms and the mucous apical pole, inducing active 
transport processes (Lehr 2000). Contact with the mucus of 
the epithelium is called muco-adhesion, and direct contact 
with the cellular membrane is called cyto-adhesion. Lectins 
are nonimmunological glycoproteins that have the capac-
ity to recognize and bind to glycoproteins exposed at the 
epithelial cell surface.
Liposomes functionalized with lecithins appeared to be 
capable of improving their binding to human alveolar cells 
(A549 and primary cells) (Abu-Dahab 2001). In this study, 
the unfunctionalized liposome formulation was optimized 
by measuring the loss of carboxyﬂ  uorescein (CF) loaded 
in the liposomes during atomization. Liposomes composed 
of DPPC–CHOL (50%–50% mol) were more stable 
during atomization (8% CF loss) than DPPC liposomes 
(15%–20% CF loss), even in the presence of pulmonary 
surfactant. Lehr (2000) reported that the atomization of 
DPPC–CHOL liposomes with lecithin functionalization 
did not signiﬁ  cantly inﬂ  uence their physical stability. The 
cell-binding capacity of functionalized liposomes is much 
higher than that of unfunctionalized liposomes, even after 
atomization
Mucoadhesive nanoparticles, coated with mucoadhesive 
polymers such as poly(acrylic acid) or chitosan, were aero-
solized in guinea pigs via the trachea (Takeuchi et al 2001). 
Chitosan-modiﬁ  ed nanospheres (CS-nanospheres), with a 
diameter of around 700–800 nm, demonstrated a slower 
elimination rate, about half that observed with unmodiﬁ  ed 
nanospheres. These results indicate that CS-nanospheres 
adhere to the mucus in the trachea and in the lung tissues as a 
result of the mucoadhesive properties of chitosan and release 
the drug in the lung over a prolonged period of time. The 
bioactivity of encalcotin encapsulated in CS- and unmodiﬁ  ed 
nanospheres were compared with the bioactivity of elcatonin 
in solution (100 IU/kg) after aerosolization. Unmodiﬁ  ed 
nanospheres and the drug solution induced a temporary fall 
in blood calcium levels after administration, returning to 
normal after 8 hours, whereas CS-nanospheres induced a 
signiﬁ  cantly prolonged reduction in blood calcium lasting 
over 24 hours. It is believed that the unmodiﬁ  ed nanospheres 
are rapidly eliminated from the lung before they are able to 
release the drug. The prolonged pharmacological effects 
of CS-nanospheres may be attributed to their adherence to 
lung tissue, meaning that they remain there for a consider-
able period of time. These results show that mucoadhesive 
nanospheres may be useful for the pulmonary delivery of 
peptide drugs.
Mucoadhesive microspheres of hydroxypropylcellulose 
(HPC) encapsulating beclomethasone dipropionate (BDP) 
were administered as powder aerosols to healthy or asthmatic 
guinea pigs (Sakagami et al 2001). The pharmacokinetics 
and pharmacodynamics of BDP were compared for different 
BDP formulations: pure crystalline BDP (cBDP), amorphous 
BDP incorporated in HPC microspheres (aBDP-HPC), and 
crystalline BDP-loaded HPC microspheres (cBDP-HPC). 
Powder aerosols were produced within a respirable size range 
of 1.7–2.9 µm. The pharmacokinetic proﬁ  les for these three 
powders were dissolution modulated. It was shown that at 
180 minutes postadministration, more than 95% and 85% 
of BDP were absorbed from the lung following aBDP-HPC 
and cBDP administration, respectively; whereas 86% of 
BDP were absorbed at 180 minutes following cBDP-HPC 
administration. Prolonged lung retention of BDP may be 
beneﬁ  cial in maximizing the efﬁ  cacy of BDP dose delivery 
to the lung and in reducing the side effects caused by its extra 
lung absorption. The duration of inhibition of eosinophil inﬁ  l-
tration into the airways of asthma-induced guinea pigs was 
assessed following cBDP and cBDP-HPC administration. 
While cBDP (1.37 mg.kg–1) inhibited eosinophil inﬁ  ltration 
for only 1–6 hours, cBDP-HPC, with a lower drug dosage 
(0.25 mg.kg–1), was able to maintain these inhibitory effects 
for 24 hours following administration. This study showed that 
this HPC microsphere system has the potential to prolong the 
therapeutic duration of BDP following inhalation.
Immunospeciﬁ  c systems
Immunoliposomes – liposomes carrying speciﬁ  c antibodies – 
can target cells carrying a speciﬁ  c antigen. Margalit (1995) 
reported that they have been used to target pulmonary tumors 
in vitro and in vivo.
Conclusion and perspectives
As discussed in this review, the pulmonary drug delivery 
ﬁ  eld is truly one of the most up-and-coming areas in today’s 
applied pharmaceutical research. The reason is not because 
of the recent launch of inhaled insulin but the fact that pul-
monary delivery still offers many white areas on the map. 
Indeed, still at this time, the more information is collected 
the more related question marks are surfacing covering 
the area of lung physiology and diseases, lung deposition, 
intelligent inhalation devices, delivery of biopharmaceu-
ticals, absorption enhancement, controlled drug release in 
the lung and, last but not least, the topic of vaccination of International Journal of Nanomedicine 2008:3(1) 16
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the lung. From the examples exposed in this review, it can be 
concluded that, at present time, it is indeed possible to some 
extend to deliver larger drug molecules such as insulin and 
heparin systematically up to therapeutic drug levels.
Several reasons can be advanced to justify the long time 
which was necessary for the ﬁ  rst pulmonary product to reach 
market approval.
First of all the physiology of the lung is not designed to 
absorb drug compounds systemically despite the very frag-
ile and vulnerable nature of the epithelium. As an interface 
between the body’s circulation and the outside air its func-
tion is to exchange only gas molecules and it has built up a 
strong defense against any other components that may enter 
the lung by accident. The defense can be by either physical 
by mucosal clearance or physiological by a strong presence 
of macrophages and enzymes. The lung can also develop 
immunological reactions against unwanted entities such as 
viruses. Secondly, a drug molecule needs to pass the physical 
clearance system represented by the upper airways and reach 
preferably the deep lung. Thirdly, once deposited in the lung 
periphery, it should avoid the biological defense mechanism 
and be absorbed by the alveolar epithelium. Consequently, in 
order to reach the lung periphery as efﬁ  ciently as possible, 
several state-of the art devices haven been developed. The 
most prominent ones in the case of insulin are developed 
by Nektar Therapeutics (Exubera® inhaler) and Aradigm 
(AERx), where a deﬁ  ned particle cloud is generated which 
can be efﬁ  ciently administered through slow inhalation by 
the patient. Besides these ones, other intelligent inhalation 
devices were also developed like the Akita technology. Akita 
is equipped with a “smartcard” that contains the patient’s 
physiological lung function data so that the inhalation 
maneuver can be adapted to the individual lung. Last year 
a pediatric device was also introduced to the market that 
translates the electronically controlled features of the Akita 
device very nicely by mechanical means. In this case, the 
inhalation volume is deﬁ  ned by the size of the balloon in 
the device chamber and the inhalation velocity is controlled 
by the air-inlet valve at the back of the device. The aerosol 
can be nebulized into the device by, for example, any com-
mercially available metered dose inhaler (MDI) system that 
is connected to the mouthpiece of the device. In line with the 
most recent European regulations that emphasize the need to 
design suitable application tools for children, this is certainly 
one of the inventive highlights in the pulmonary ﬁ  eld besides 
the launch of Exubera®.
What can be expected in the near future? Which conclu-
sions can be drawn from the past experimental facts?
In spite of the numerous developments of nanocarriers 
intended for pulmonary drug delivery, today it appears more 
and more that the use of controlled drug releasing systems in 
the lung is a controversial issue. Beyond academic attempts, 
not many commercial solutions have emerged so far. The 
major reason is the highly efﬁ  cient physiological defense 
system for particulates in the lung that is difﬁ  cult to over-
come. As soon as a foreign particle is observed in the lung 
tissue a powerful macrophage reaction is launched to attack 
the particle. Probably, the most promising approaches involve 
the use of stealth approaches, such as PEGylation or the use 
of endogenous compounds that occur in the lung such as 
dipalmitoylphosphatidylcholine (DPPC). DPPC can be co-
formulated into liposomes that encapsulate a drug compound 
for prolonged release as shown recently in an interesting 
study based on these ﬁ  ndings and using the AeroLEF system 
(aerosolized Liposomal Encapsulated Fentanyl).
Another future interesting application of the pulmonary 
route is the delivery of vaccines. Besides providing a conve-
nient alternative to needle injections it also has shown to be 
more efﬁ  cient in antibody responses than injected vaccine 
in a recently published article by Bennett et al (2002). This 
concept would really beneﬁ  t compliance of patients that are 
otherwise difﬁ  cult to reach. In particular, in economically 
less fortunate regions in the world where infectious diseases 
are strong threats to quality of life and one of the major 
causes of mortality, vaccination programs by inhalation can 
be regarded as a clear advantage of invasive administration. 
Due to its interesting potential, this area will be another hot 
topic in the ﬁ  eld of pulmonary drug delivery for the coming 
10 years.
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